论文部分内容阅读
目的：评价顺铂 (cisplatin,DDP)＋ 5-氟尿嘧啶 (5- fluorouracil,5- FU)(PF),阿霉素 (adriamycin,ADM)＋ DDP＋ 5- FU(APF)，异环磷酰胺 (ifosfamide,IFO)＋ DDP＋ 5- FU(IPF),IFO＋ DDP(IP)方案分别治疗晚期及复发转移鼻咽癌的近期疗效及毒副作用。方法：同一化疗方案的病例列为一组 ,PF组 19例， APF组 22例， IP组 30例， IPF组 26例。分别总结四种方案的有效率，对肺转移的有效率，白细胞下降、恶心、呕吐的发生率，并将 APF、 IP、 IPF方案分别与 PF方案的各项结果进行统计分析。结果： PF组、 APF组、 IP组和 IPF组的有效率分别为 42.11％、 54.55％、 73.33％、 76.92％， IP方案、 IPF方案的有效率与 PF方案比有显著性差异 (P< 0.05)。 PF组、 APF组、 IP组和 IPF组对肺转移的有效率分别为 55.56％、 60 00％、 88.90％、 88.20％， IP方案与 PF方案比有显著性差异 (P< 0.05)。Ⅲ～Ⅳ度白细胞下降发生率 IP方案较 PF方案有显著性差异 (P< 0.05)， IPF方案较 PF方案有极显著性差异 (P< 0.01)。四种方案恶心、呕吐的发生率均无显著性差异 (P >0.05)。结论： IP及 IPF方案均是治疗晚期及复发、转移鼻咽癌可供选择的化疗方案。
OBJECTIVE: To evaluate the efficacy and safety of cisplatin (DDP) plus 5-fluorouracil (PF), adriamycin (ADM), DDP + 5- FU (APF), ifosfamide , IFO) + DDP + 5- FU (IPF) and IFO + DDP (IP) regimens respectively for the treatment of advanced and recurrent nasopharyngeal carcinoma. Methods: The same chemotherapy regimen as a group of 19 cases, PF group 22 cases, APF group 30 cases, IPF group 26 cases. The efficiency of four schemes, the effective rate of lung metastasis, the incidence of leukopenia, nausea and vomiting were summarized respectively. The results of APF, IP and IPF were compared with those of PF respectively. Results: The effective rates of PF group, APF group, IP group and IPF group were 42.11%, 54.55%, 73.33% and 76.92% respectively. The effective rates of IP and IPF were significantly different from those of PF (P <0.05) ). The effective rate of pulmonary metastasis in PF group, APF group, IP group and IPF group were 55.56%, 60.00%, 88.90% and 88.20%, respectively. There was a significant difference between IP regimen and PF regimen (P <0.05). The incidence of Ⅲ ~ Ⅳ leukopenia in IP regimen was significantly higher than that of PF regimen (P <0.05), and the IPF regimen was significantly different from PF regimen (P <0.01). Four programs nausea, vomiting no significant difference (P> 0.05). Conclusion: Both IP and IPF regimens are available regimens for the treatment of advanced and recurrent and metastatic nasopharyngeal carcinoma.